Evidence Based Efficacy of Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF) in Acute and Chronic Wound Healing: A Retrospective Case Series

Background: Wound healing is a complex biological process often significantly impaired in chronic wounds such as diabetic ulcers, venous stasis ulcers, and pressure injuries diabetic foot ulcers, venous stasis ulcers, and pressure sores (Autologous platelet concentrates-Platelet-Rich Plasma (PRP), Injectable Platelet-Rich Fibrin (i-PRF), and PRF membranes-have emerged as promising effective regenerative therapies due to their high concentration of growth factors, cytokines, bioactives substances, and their ability to enhance tissue repair. Objective: This retrospective study aimed to evaluate the clinical efficacy and safety of PRP, i-PRF, and PRF membranes in the treatment of acute and chronic cutaneous wounds over a seven-year period in a Swiss regenerative medicine center. Methods: A total of 25 patients aged 22-95 years with various wound etiologies were treated with PRP, i-PRF, and/or PRF membranes. Wound size, healing time, pain (VAS score), and patient-reported outcomes were assessed. Hematological analysis of platelet products was performed using the Sysmex(R) analyzer. Results: The mean healing time was 7.8 ± 9.0 weeks. Pain intensity decreased by 72% (VAS score from 5.88 to 1.63). Complete wound closure was achieved in 47.1% of cases, with a mean surface area improvement of 50%. Venous ulcers showed the most significant response (91% improvement, 82% complete healing), followed by burns and surgical wounds. Platelet concentration increased on average by a factor of 2.35 after centrifugation. No serious adverse events were reported. Conclusion: PRP, i-PRF, and PRF membranes are effective and well-tolerated treatments for acute and chronic wounds, offering significant clinical improvement in wound closure, pain reduction, and patient satisfaction. These findings support the integration implementation of autologous plasmatherapy into personalized wound management strategies. Larger, randomized controlled trials are warranted needed to establish standardized protocols and validate long-term efficacy protocols.